

## USA Medicare Changes Withdrawn

### Highlights:

- **All five MACs have today announced that proposed USA reimbursement changes will not go into effect.**
- **Canaloplasty procedures performed with the Company's *iTrack*™ portfolio of canaloplasty devices will continue to be medically reimbursed without change.**
- **Sales growth in the USA is expected to continue.**

Nova Eye Medical Limited (ASX: EYE) (**Nova Eye Medical** or the **Company**), today announces that the Local Coverage Determinations ("LCDs") for minimally invasive glaucoma surgery (MIGS) proposed by five<sup>1</sup> Medicare Administrative Contractors ("MACs") and scheduled to become effective on January 29, 2024, will not go into effect.

The LCDs had proposed to restrict or deny coverage for several MIGS procedures, including canaloplasty.

The announcements posted by the MACs means that there will be no change in the status of reimbursement coverage for canaloplasty after January 2024. Accordingly, canaloplasty procedures performed with the Company's *iTrack*™ portfolio of canaloplasty devices will continue to be reimbursed in all states in the USA.

According to Nova Eye Medical CEO, Tom Spurling, this is a positive development for USA sales of the Company's new *iTrack*™ *Advance* canaloplasty device, which has achieved significant market penetration following its launch in May 2023.

"Surgeon appetite in the USA for our new *iTrack*™ *Advance* canaloplasty device has been strong and this announcement by the MACs will support continued sales growth following the recent period of confusion in the market arising from the LCDs."

"The canaloplasty procedure was first reported in the scientific literature in 1999 and has established a strong reputation for clinical effectiveness and safety. We appreciate the efforts of the key societal groups, including the American Glaucoma Society (AGS), the American Society of Cataract and Refractive Surgery (ASCRS) and the American Academy of Ophthalmology (AAO), who advocated for the canaloplasty procedure during the review process with the MACs. Along with thousands of determined ophthalmologists who petitioned against the proposed changes, the societies played a critical role in ensuring glaucoma patients in the USA have continued access to canaloplasty."

***This release dated December 29, 2023 has been authorised for lodgement to ASX by the Board of Directors of Nova Eye Medical Limited and lodged by Simon Gray, Company Secretary.***

1. The five MACs are National Government Services, WPS Government Health Administrators, Palmetto GBA, Celerian Group Company, and Noridian Healthcare Solutions

– ENDS –

**Company**

Tom Spurling  
Managing Director  
+61 417 818 658  
[tspurling@nova-eye.com](mailto:tspurling@nova-eye.com)

**Company**

Kate Hunt  
Chief Commercial Officer  
+61 404 080 679  
[khunt@nova-eye.com](mailto:khunt@nova-eye.com)

**Investors**

Mark Flynn  
Investor Relations  
+61 416 068 733  
[mflynn@nova-eye.com](mailto:mflynn@nova-eye.com)

---

**ABOUT NOVA EYE MEDICAL**

Nova Eye Medical Limited is a medical technology company that develops, manufactures and sells a portfolio of proprietary ophthalmic treatment technologies and devices. Used by eye surgeons globally, these technologies include iTrack™ minimally invasive glaucoma surgery (MIGS), a consumable surgical device that restores the eye's natural outflow pathway to lower pressure inside the eye and to eliminate patient reliance on anti-glaucoma medications for mild-moderate glaucoma. The Molteno3® glaucoma drainage device platform is designed to enhance surgical utility and optimize clinical outcomes for long-term IOP control in cases of severe glaucoma. It also offers the benefit of a simplified and faster surgical procedure. With its sales headquarters based in Fremont, California, Nova Eye Medical is supported by a global network of distribution partners. Manufacturing facilities are located in Fremont, California and Dunedin, New Zealand.

For additional information about Nova Eye Medical and its technologies, please visit: [www.nova-eye.com](http://www.nova-eye.com)